Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $126.00 Average PT from Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $126.00.

Several research firms have recently weighed in on LNTH. Leerink Partners raised their price objective on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research report on Thursday, July 11th. JMP Securities cut their price objective on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a report on Thursday, August 1st. Redburn Atlantic assumed coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective on the stock. Truist Financial dropped their target price on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. Finally, B. Riley increased their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research report on Thursday, July 25th.

Insider Buying and Selling at Lantheus

In other news, President Paul Blanchfield sold 2,000 shares of the business's stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now directly owns 98,980 shares of the company's stock, valued at approximately $9,540,682.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the firm's stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now directly owns 98,980 shares in the company, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Mary Anne Heino sold 10,481 shares of the company's stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the transaction, the director now owns 454,923 shares in the company, valued at $43,445,146.50. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,852 shares of company stock worth $3,922,001. 1.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lantheus

Several institutional investors and hedge funds have recently added to or reduced their stakes in LNTH. Vanguard Group Inc. lifted its position in Lantheus by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock valued at $458,271,000 after acquiring an additional 389,828 shares during the period. Farallon Capital Management LLC lifted its holdings in shares of Lantheus by 53.7% during the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock valued at $182,999,000 after purchasing an additional 796,000 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in shares of Lantheus by 25.3% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock worth $121,867,000 after purchasing an additional 394,837 shares in the last quarter. Reinhart Partners LLC. grew its stake in shares of Lantheus by 8.4% in the 1st quarter. Reinhart Partners LLC. now owns 1,470,383 shares of the medical equipment provider's stock worth $91,517,000 after buying an additional 114,110 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Lantheus by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider's stock worth $99,525,000 after buying an additional 19,071 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Price Performance

Lantheus stock traded up $1.22 during midday trading on Friday, reaching $107.79. 296,412 shares of the stock were exchanged, compared to its average volume of 997,925. The company's fifty day moving average is $103.77 and its 200-day moving average is $87.76. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. Lantheus has a 52 week low of $50.20 and a 52 week high of $126.89. The firm has a market cap of $7.47 billion, a PE ratio of 16.46 and a beta of 0.50.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. During the same quarter in the previous year, the firm earned $1.40 earnings per share. Lantheus's quarterly revenue was up 22.5% compared to the same quarter last year. On average, sell-side analysts forecast that Lantheus will post 5.99 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.